A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Trial Profile

A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Bladder cancer; Brain cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Biomarker; Pharmacodynamics
  • Acronyms IPINIVO
  • Sponsors Agenus
  • Most Recent Events

    • 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 22 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top